NeuTec wants to make visiting the hospital an experience that lessens patient dangers. The biopharmaceutical company identifies and compares antibodies produced by patients who recover from infections (acquired in hospitals) to those produced by patients who die. Then, using its FabTec technology, it develops genetically recombinant antibodies, or "grabs," to treat patients with life-threatening infections. The company's two leading candidates, Mycograb, which targets a fungus in the mouth and skin, and Aurograb, which targets bacterial infections, are in clinical trials in the UK. Mycograb also is in clinical trials in the US.

SurModics, Inc. Company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. SurModics, Inc. engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry. The company operates through four business units: Cardiovascular, Ophthalmology, SurModics Pharmaceuticals, and In Vitro Technologies. The Cardiovascular business unit supports the drug delivery and surface modification needs of cardiovascular customers by providing drug delivery polymers and coating technologies, including advanced lubricity (slippery) coatings that ease placement and maneuverability of medical devices in the body. The Ophthalmology business unit develops drug delivery systems for various drugs and other bioactive agents developed by pharmaceutical and ophthalmology companies for the treatment of serious eye diseases.The SurModics Pharmaceuticals business unit specializes in proprietary injectable microparticles and implants based on biodegradable polymers to provide sustained delivery of drugs, as well as supplies biodegradable polymers to corporate and academic customers. The In Vitro Technologies business unit specializes in in vitro diagnostic products and technologies for the biomedical research and medical diagnostic markets. Its products and technologies include protein stabilization reagents, substrates, recombinant autoimmune antigens, surface chemistry technologies for nucleic acid and protein immobilization, and diagnostic format intellectual property. The company markets its technologies and products through sales professionals, as well as sales and marketing relationships with third-parties worldwide. It has collaboration agreements with Genzyme Corporation to develop novel drug delivery solutions with an initial focus on peptide delivery.

ImClone Systems has one drug and it is making the most of it. The drug development company's only product on the market, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb in North America and with Merck KGaA elsewhere. ImClone is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. The company is also working on additional oncology-related antibody therapies. In 2008 ImClone was acquired by Eli Lilly for $6.5 billion, after rejecting bids from Bristol-Myers Squibb.

Teikoku Pharma USA is a wholly-owned subsidiary of Teikoku Seiyaku Inc., a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain and CNS. By applying our transdermal technologies to existing actives or co-developing new formulations, Teikoku helps pharmaceutical companies extend patent protections, diversify product lines, provide better delivery mechanisms, and promote brand loyalty. Teikoku charts new territory in prescription, OTC, and medical device markets around the world, transforming ideas into ideally delivered products that carry a competitive edge in quality and innovation.

Advion develops, manufactures and globally supports mass spectrometers, novel sample introduction and assay solutions, chip- based ion sources, chromatography systems, microfluidic flow chemistry systems and consumables for life science and related industries. We seek to enhance analysis performance and workflows. Using our deep scientific and engineering knowledge of mass spectrometry and microfludics, we leverage our passionate employees’ commitment to create quality, flexible and fit-for- purpose solutions.

William Ransom & Son plc is a United Kingdom-based company engaged in the supply of branded natural health products, vitamins and food supplements, the manufacture of pharmaceutical products and the extraction of plant material for the pharmaceutical, food and beverage industries. The Company operates in three divisions: consumer healthcare, pharmaceutical and natural products. Consumer healthcare includes the sale of consumer-branded healthcare products. The pharmaceutical division includes the manufacture of its own Medicines and Healthcare Products Regulatory Agency (MHRA)-licensed products, as well as pharmaceuticals and over-the-counter products for third parties. The natural products division includes the manufacture of botanical extracts used as ingredients by the pharmaceutical division and sold to third parties.

CytRx Corporation company was founded in 1985 and is headquartered in Los Angeles, California. CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology.

Cedarburg Hauser, formerly Cedarburg Pharmaceuticals, makes drugs, components of drugs, and ingredients for drugs. The contract manufacturer does everything from project management to manufacturing to validating study results. It produces custom chemicals, natural and synthetic active pharmaceutical ingredients, dietary supplements, and cosmetics. And, because Cedarburg Hauser also holds Drug Enforcement Agency permits, it makes controlled substances including pain killers and other narcotics. Other services include process development and a whole host of analytical services including quality control and stability studies.

Kyorin, founded in 1923, already has affiliates and subsidiaries in Germany and the US. KYORIN Co., Ltd. is a Japan-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates in two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sale of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the manufacture of clinical testing products, as well as the research of new drugs and candidate compounds. The Others segment is involved in the development and sale of cosmetics, as well as raw materials of medicines and cosmetics, the promotion of sales, the planning and production of advertisements, the sale of packaging materials, in addition to the provision of advisory services and the operational management of funds.

Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products. The Company’s activity includes improving off-patent drug products for life cycle management and developing generic versions of controlled-release drug products. Its technology is applicable to develop delayed, sustained or targeted-release pellets, capsules, tablets, granules and powders. As of March 31, 2009, the Company had two products, Lodrane 24 and Lodrane 24D, being sold commercially, and a pipeline of five additional drug candidates under active development in the therapeutic areas that include pain management, allergy and infection. Of the products under development, ELI-216, a once-a-day, abuse-deterrent oxycodone product, and ELI-154, a once-a-day oxycodone product, are in clinical trials, and Elite has completed pilot studies on two of its other generic product candidates.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.